Rexahn Pharma (RNN) Receives USPTO Notice of Allowance for Patent Related to RX-3117
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Rexahn Pharmaceuticals, Inc. (NYSE: RNN) announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a patent for claims related to the synthesis of its novel anti-cancer investigational drug candidate, RX-3117. RX-3117 is currently in stage 2 of a Phase Ib/IIa clinical trial in patients with metastatic pancreatic cancer.
"Rexahn is pleased to expand the intellectual property protection for RX-3117, which has shown preliminary efficacy in stage 1 of a Phase Ib/IIa clinical trial in patients with metastatic pancreatic cancer," commented Peter D. Suzdak, Ph.D., Chief Executive Officer of Rexahn. "This latest patent for RX-3117 is an important addition to our overall intellectual property estate and further strengthens our global patent position for RX-3117."
Data from stage 1 of a Phase Ib/IIa clinical trial was recently presented at The European Society for Medical Oncology (ESMO) congress. Patients with relapsed or refractory metastatic pancreatic cancer, 88% of whom had received 4 or more prior cancer therapies, were treated with RX-3117. There are no approved treatments for pancreatic cancer patients who have failed three or more prior therapies and their survival is usually less than 2 months. These patients would usually be offered palliative or best supportive care. In this study more than 20% of patients treated with RX-3117 exhibited progression free survival of greater than 4 months. An additional 20%, for a total of 40%, of the patients exhibited progression free survival of 2.5 months. Based on positive results, stage 2 of the study has been initiated and an additional 40 pancreatic cancer patients are currently being enrolled. Rexahn has received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for RX-3117 for pancreatic cancer.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PICO Holdings (PICO) Announces Leadership, Governance Changes; Terminates Central Square Agreement
- Delta Air Lines (DAL) Names New Chief Communications Officer
- Shire's (SHPG) Phase 3 Investigational Study of VONVENDI Meets Primary Endpoint in Controlling Bleeding in Adults with VWD
Create E-mail Alert Related CategoriesCorporate News, Litigation
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!